masivet
ab science s.a. - masitinib mesilate - antineoplastische mittel - hunde - behandlung von nicht resektablen mastzelltumoren (grad 2 oder 3) mit bestätigtem mutiertem c-kit-tyrosinkinaserezeptor.
masiviera
ab science - masitinib - pankreas-tumoren - protein-kinase-inhibitoren - behandlung von nicht resektablen, lokal fortgeschrittenen oder metastasiertem bauchspeicheldrüsenkrebs.
masipro
ab science - masitinib mesilate - mastozytose - antineoplastische mittel - behandlung der mastozytose.
masican
masitinib - gastrointestinale stromatumoren - protein-kinase-inhibitoren - behandlung von nicht resezierbarem und/oder metastasiertem malignen gastrointestinalen stromatumoren tumor (gist).
alsitek
ab science - masitinib mesilate - amyotrophe lateralsklerose - antineoplastische mittel - behandlung der amyotrophen lateralsklerose.
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
dasatinib krka 20 mg filmtablette
krka, d.d. novo mesto - dasatinib - filmtablette - 20 mg - dasatinib 20 mg - dasatinib
dasatinib krka 50 mg filmtablette
krka, d.d. novo mesto - dasatinib - filmtablette - 50 mg - dasatinib 50 mg - dasatinib
dasatinib krka 70 mg filmtablette
krka, d.d. novo mesto - dasatinib - filmtablette - 70 mg - dasatinib 70 mg - dasatinib